HairDX Genetic Test
Commercial- Indications
- Androgenetic alopecia
Company intelligence / Profile preview
HairDX was the first company to commercialize genetic tests predicting risk of male and female pattern baldness using analysis of the androgen receptor gene. The test provided consumers with a CAG repeat score indicating their likelihood of developing androgenetic alopecia. The company also initiated a clinical trial on genetically tailored drug therapy for female baldness but no recent results are available. In recent years, the HairDX portfolio was acquired by Daniel Alain, Inc., which continues to market these diagnostic products alongside new offerings.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HairDX.